FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS

Their core work

FIND is a Geneva-based global non-profit organization dedicated to accelerating the development and delivery of diagnostic tests for infectious diseases, particularly in low-resource settings. In H2020, they contribute clinical trial expertise, diagnostic validation capabilities, and health economics analysis to large international consortia tackling tuberculosis, antimicrobial resistance, filovirus detection, and leishmaniasis. Their role bridges the gap between laboratory research and field-deployable diagnostic tools, bringing real-world testing infrastructure and regulatory pathway knowledge to research partnerships.

What they specialise in

How they've shifted over time

FIND's early H2020 involvement (2015-2017) centered on specific neglected diseases — leishmaniasis and filovirus outbreaks — reflecting their emergency and tropical disease roots. From 2019 onward, their focus broadened significantly to include wearable diagnostic technology (A-Patch), health economics of diagnostics (VALUE-Dx), and AI-driven clinical trial platforms for tuberculosis (UNITE4TB). The shift signals a move from disease-specific diagnostic validation toward systemic, technology-enabled approaches to diagnostics and treatment optimization.

FIND is moving from field-testing specific diagnostic tools toward building AI-powered clinical trial platforms and evaluating the health-economic case for diagnostics, positioning them as a systems-level partner rather than a single-disease specialist.

How they like to work

FIND operates exclusively as a participant or third party — never as coordinator — which is consistent with their role as a specialized contributor bringing diagnostic expertise into larger research consortia. With 93 unique partners across 21 countries, they are a highly networked organization that works in large, diverse consortia (particularly IMI2 public-private partnerships). This makes them an accessible and experienced partner, comfortable operating within complex multi-stakeholder projects without needing to lead them.

With 93 consortium partners spanning 21 countries, FIND maintains one of the broader collaboration networks for an NGO of its size. Their reach is truly global, anchored in European research but connected to institutions worldwide through their diagnostic development mission.

What sets them apart

FIND occupies a rare niche as a non-profit diagnostic accelerator — they are neither a university lab nor a company, but an organization specifically built to move diagnostic tests from research into real-world use. Their combination of clinical validation expertise, health economics knowledge, and field deployment experience makes them uniquely valuable for any consortium that needs to demonstrate that a diagnostic innovation actually works outside the lab. For consortium builders, FIND brings credibility with regulators, access to clinical trial sites in low-resource settings, and a track record in IMI public-private partnerships.

Highlights from their portfolio

• UNITE4TB
  Largest funded project (EUR 1.1M to FIND) running until 2028, combining AI with innovative clinical trial design for tuberculosis — represents their strategic direction.
• A-Patch
  Unusual crossover into wearable sensor technology for autonomous disease detection on skin, showing FIND's expansion beyond traditional lab diagnostics.
• VALUE-Dx
  Directly addresses the economic argument for diagnostics in fighting antimicrobial resistance — a major global health priority with strong policy relevance.